Laboratorios Farmaceuticos ROVI SA
MAD:ROVI

Watchlist Manager
Laboratorios Farmaceuticos ROVI SA Logo
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Watchlist
Price: 49.04 EUR -4.41% Market Closed
Market Cap: 2.5B EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ROVI stock under the Base Case scenario is 67.22 EUR. Compared to the current market price of 49.04 EUR, Laboratorios Farmaceuticos ROVI SA is Undervalued by 27%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ROVI Relative Value
Base Case
67.22 EUR
Undervaluation 27%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.3
P/S
P/S
Price to Sales
3.3
vs History
53
vs Industry
43
Median 3Y
3.3
Median 5Y
3.5
Industry
2.4
Forward
3.4
More Details
18.3
P/E
P/E
Price to Earnings
18.3
vs History
49
vs Industry
35
Median 3Y
14.1
Median 5Y
18.4
Industry
20.5
Forward
17.7
More Details
18.1
P/OCF
P/OCF
Price to OCF
18.1
vs History
55
vs Industry
20
Median 3Y
19.7
Median 5Y
19.5
Industry
15.4
More Details
20.9
P/FCFE
P/FCFE
Price to FCFE
20.9
vs History
58
vs Industry
20
Median 3Y
27.8
Median 5Y
22.9
Industry
22.8
More Details
4.4
P/B
P/B
Price to Book Value
4.4
vs History
69
vs Industry
15
Median 3Y
5.8
Median 5Y
5.8
Industry
1.9
More Details
3.4
EV/S
EV/S
Enterprise Value to Sales
3.4
vs History
52
vs Industry
40
Median 3Y
3.4
Median 5Y
3.5
Industry
2.5
Forward
3.4
More Details
5.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.4
vs History
55
vs Industry
44
Median 3Y
5.4
Median 5Y
5.7
Industry
4.9
More Details
12.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
12.4
vs History
55
vs Industry
35
Median 3Y
10.6
Median 5Y
13
Industry
12.4
Forward
12
More Details
14.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
14.3
vs History
55
vs Industry
37
Median 3Y
11.4
Median 5Y
15
Industry
15.5
Forward
13.9
More Details
18.6
EV/OCF
EV/OCF
Enterprise Value to OCF
18.6
vs History
52
vs Industry
20
Median 3Y
20.1
Median 5Y
19.5
Industry
14
More Details
33.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
33.8
vs History
47
vs Industry
11
Median 3Y
36.6
Median 5Y
32.9
Industry
17.9
More Details
3.6
EV/IC
EV/IC
Enterprise Value to IC
3.6
vs History
68
vs Industry
20
Median 3Y
4.6
Median 5Y
4.6
Industry
1.8
More Details

Multiples Across Competitors

ROVI Competitors Multiples
Laboratorios Farmaceuticos ROVI SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
ES
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
2.5B EUR 3.3 18.3 12.4 14.3
US
Eli Lilly and Co
NYSE:LLY
699.5B USD 15.5 66.1 38.5 42.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
368.8B USD 4.2 26.2 12.3 16.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.6 19 12.5 14.3
CH
Roche Holding AG
SIX:ROG
208.7B CHF 3.6 18.2 10.2 12.1
UK
AstraZeneca PLC
LSE:AZN
167.6B GBP 4 30.7 126.3 192.8
CH
Novartis AG
SIX:NOVN
186.3B CHF 4.2 18.3 11.1 14.2
US
Merck & Co Inc
NYSE:MRK
206.3B USD 3.2 12.1 8.2 9.7
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
FR
Sanofi SA
PAR:SAN
119.8B EUR 2.7 20.9 9.1 13.3
P/E Multiple
Earnings Growth PEG
ES
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Average P/E: 25.5
18.3
23%
0.8
US
Eli Lilly and Co
NYSE:LLY
66.1
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
26.2
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
19
19%
1
CH
Roche Holding AG
SIX:ROG
18.2
16%
1.1
UK
AstraZeneca PLC
LSE:AZN
30.7
36%
0.9
CH
Novartis AG
SIX:NOVN
18.3
16%
1.1
US
Merck & Co Inc
NYSE:MRK
12.1
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
FR
Sanofi SA
PAR:SAN
20.9
28%
0.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ES
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Average EV/EBITDA: 395.1
12.4
20%
0.6
US
Eli Lilly and Co
NYSE:LLY
38.5
30%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.5
15%
0.8
CH
Roche Holding AG
SIX:ROG
10.2
8%
1.3
UK
AstraZeneca PLC
LSE:AZN
126.3
9%
14
CH
Novartis AG
SIX:NOVN
11.1
5%
2.2
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
FR
Sanofi SA
PAR:SAN
9.1
7%
1.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ES
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Average EV/EBIT: 1 698.4
14.3
23%
0.6
US
Eli Lilly and Co
NYSE:LLY
42.5
33%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.1
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.3
16%
0.9
CH
Roche Holding AG
SIX:ROG
12.1
9%
1.3
UK
AstraZeneca PLC
LSE:AZN
192.8
21%
9.2
CH
Novartis AG
SIX:NOVN
14.2
8%
1.8
US
Merck & Co Inc
NYSE:MRK
9.7
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
FR
Sanofi SA
PAR:SAN
13.3
14%
0.9

See Also

Summary
ROVI intrinsic value, competitors valuation, and company profile.
DCF Valuation
ROVI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ROVI stock valuation using valuation multiples.
Wall Street Estimates
ROVI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ROVI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 244,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.